KORONIS BEGINS TRIAL OF ANTIVIRAL HIV/AIDS THERAPEUTIC
Koronis Pharmaceuticals has begun a Phase Ib clinical trial of KP-1461, its
novel antiviral therapeutic, in HIV-positive patients. The objectives of the
trial are to evaluate the safety, toxicity, pharmacokinetic profile and initial
clinical activity of KP-1461. The trial is being conducted at several HIV treatment
centers in the U.S.
KP-1461 is a first-in-class therapeutic designed to overcome the problem of drug resistance that has emerged with approved HIV treatments. KP-1461 has a novel mechanism of action designed to eliminate HIV by selectively increasing its natural mutation rate to a point that it can no longer replicate. Unlike currently approved HIV treatments enzyme and fusion inhibitors that work to block virus activation and replication, KP-1461 targets HIV mutation to force the production of a nonfunctional virus.
The multicenter, randomized, double-blind, placebo-controlled, dose-escalation study is currently open to enroll approximately 40 HIV-positive patients who have previously failed highly active antiretroviral regimens.